Key Insights

Highlights

Treatment Research

2 treatments under study, led by Imtox25

Related Conditions

Often studied with 14 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

50.0%

1 terminated out of 2 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

2Total
Phase 1 (1)
Phase 2 (1)

Trial Status

Suspended1
Terminated1

Clinical Trials (2)

Showing 2 of 2 trials
NCT05377827Phase 1Suspended

Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies

NCT01378871Phase 2TerminatedPrimary

A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma

Showing all 2 trials

Research Network

Common Treatments

  • Imtox251
  • Wucart0071

Active Sponsors

  • Washington University School of Medicine1
  • Allotera Therapeutics1
  • Amit Verma1

Top Investigators

Related Conditions

  • Adult T Cell Lymphoma2
  • Angioimmunoblastic Tcell Lymphoma1
  • Primary Cutaneous Gammadelta Tcell Lymphoma1
  • Extranodal Nktcell Lymphoma1
  • Acute Myeloid Leukemia1

Activity Timeline